Cite
HARVARD Citation
Dignass, A. et al. (n.d.). P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease. Journal of Crohn's and colitis. pp. S459-S460. [Online].